Cargando…
A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers
Background and Objective: Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect. Dextromethorphan, the active ingredient, is a low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. This study evaluated the potential for a drug-d...
Autores principales: | Pope, Laura E., Schoedel, Kerri A., Bartlett, Cynthia, Sellers, Edward M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714141/ https://www.ncbi.nlm.nih.gov/pubmed/22712629 http://dx.doi.org/10.1007/BF03261905 |
Ejemplares similares
-
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect
por: Schoedel, Kerri A, et al.
Publicado: (2014) -
Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease
por: Khoury, Rita
Publicado: (2021) -
Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia
por: Tampi, Rajesh R, et al.
Publicado: (2020) -
Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis
por: Tabor Gray, Lauren, et al.
Publicado: (2023) -
Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect
por: Pioro, Erik P.
Publicado: (2014)